TY - JOUR
T1 - Short-term topical bevacizumab in the treatment of stable corneal neovascularization
AU - Cheng, Sheng Fu
AU - Dastjerdi, Mohammad H.
AU - Ferrari, Giulio
AU - Okanobo, Andre
AU - Bower, Kraig S.
AU - Ryan, Denise S.
AU - Amparo, Francisco
AU - Stevenson, William
AU - Hamrah, Pedram
AU - Nallasamy, Nambi
AU - Dana, Reza
N1 - Funding Information:
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest and none were reported. Supported in part by Grant K24 EY019098 from the National Institutes of Health , Bethesda, Maryland; and by Prevent Blindness America , Chicago, Illinois. Involved in Design of study (M.H.D., R.D.); Conduct of study (S.-F.C., M.H.D., K.S.B., R.D.); Collection of data (K.S.B., P.H., R.D.); Management, analysis, and interpretation of data (S.-F.C., M.H.D., G.F., A.O., D.S.R., F.A., W.S., N.N., R.D.); and Preparation of manuscript (S.-F.C., W.S., R.D.). This was a prospective protocol-driven study approved by the institutional review boards of the Massachusetts Eye & Ear Infirmary and Walter Reed Army Medical Center. The study also complied with the Health Insurance Portability and Accountability Act. Informed consent was obtained from all patients before enrollment. The clinical trial was registered (registration no.: NCT00559936 ) and can be accessed on the web site www.clinicaltrials.gov . The authors thank Leila Smaga, Massachusetts Eye & Ear Infirmary, for her invaluable support in the clinical trial management.
PY - 2012/12
Y1 - 2012/12
N2 - Purpose: To evaluate the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization. Design: Prospective, nonrandomized, interventional case series. Methods: setting: Institutional, multicenter clinical trial. study population: Twenty eyes from 20 patients with stable corneal neovascularization. intervention procedures: Patients were treated with topical 1.0% bevacizumab for 3 weeks and were monitored for a total of 24 weeks. main outcome measures: Primary outcome measures included: neovascular area, defined as the area of the corneal vessels themselves; vessel caliber, defined as the mean corneal vessel diameter; and invasion area, defined as the fraction of the total cornea into which the vessels extended. The occurrence of ocular and systemic adverse events was monitored closely. Results: As compared with the baseline visit, patients exhibited a statistically significant improvement in neovascular area by week 6 (P =.007) and in vessel caliber by week 12 (P =.006). At the final visit, neovascular area, vessel caliber, and invasion area were reduced by 47.5%, 36.2%, and 20%, respectively. The decreases in neovascular area and vessel caliber were statistically significant (P <.001 and P =.003, respectively); however, the reduction in invasion area did not reach statistical significance (P =.06). There were no significant changes in the secondary outcomes, and there were no adverse events. Conclusions: Short-term topical bevacizumab treatment reduced the extent of stable corneal neovascularization as measured by neovascular area and vessel caliber with no associated adverse events. Interestingly, the degree of treatment efficacy was inversely proportional to the baseline invasion area.
AB - Purpose: To evaluate the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization. Design: Prospective, nonrandomized, interventional case series. Methods: setting: Institutional, multicenter clinical trial. study population: Twenty eyes from 20 patients with stable corneal neovascularization. intervention procedures: Patients were treated with topical 1.0% bevacizumab for 3 weeks and were monitored for a total of 24 weeks. main outcome measures: Primary outcome measures included: neovascular area, defined as the area of the corneal vessels themselves; vessel caliber, defined as the mean corneal vessel diameter; and invasion area, defined as the fraction of the total cornea into which the vessels extended. The occurrence of ocular and systemic adverse events was monitored closely. Results: As compared with the baseline visit, patients exhibited a statistically significant improvement in neovascular area by week 6 (P =.007) and in vessel caliber by week 12 (P =.006). At the final visit, neovascular area, vessel caliber, and invasion area were reduced by 47.5%, 36.2%, and 20%, respectively. The decreases in neovascular area and vessel caliber were statistically significant (P <.001 and P =.003, respectively); however, the reduction in invasion area did not reach statistical significance (P =.06). There were no significant changes in the secondary outcomes, and there were no adverse events. Conclusions: Short-term topical bevacizumab treatment reduced the extent of stable corneal neovascularization as measured by neovascular area and vessel caliber with no associated adverse events. Interestingly, the degree of treatment efficacy was inversely proportional to the baseline invasion area.
UR - http://www.scopus.com/inward/record.url?scp=84869087247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869087247&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2012.06.007
DO - 10.1016/j.ajo.2012.06.007
M3 - Article
C2 - 22967868
AN - SCOPUS:84869087247
SN - 0002-9394
VL - 154
SP - 940-948.e1
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 6
ER -